Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, And Segment Forecasts, 2023 - 2032

Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, And Segment Forecasts, 2023 - 2032



The global uterine fibroid treatment market size is expected to reach USD 10.83 billion by 2032, according to a new study by Polaris Market Research. The report “Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, And Segment Forecasts, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Uterine fibroids (UF) are a common condition affecting women of reproductive age, with heavy menstrual bleeding being one of the most common symptoms. The development of novel drugs, such as GnRH antagonists and progestin-releasing IUDs, has provided more effective treatment options for women with uterine fibroids. These factors, along with increased awareness and diagnosis, are driving the growth of the market.

As per the analysis done by the IntechOpen, excessive menstrual bleeding is the most common symptom in the UF, affecting almost 1.4 Mn women each year. Moreover, around 60 percent of the women have reported the symptoms of physical in-activity and quality of life.

Demand for more effective and safer treatment options for uterine fibroids is increasing, and this is driving research and development efforts in the field. With increased funding for research activities, the development of more advanced and innovative treatment options is expected, which will further drive the growth of the market. Additionally, the development of personalized medicine and precision therapies is also expected to drive growth in the market, as these approaches may offer more targeted and effective treatment options for individual patients.

The recent endorsement and reintroduction of the Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021 by the Society for Women's Health Research (SWHR) will provide funding and support for research on uterine fibroids, which is expected to boost the development of novel treatments. Additionally, the recent approval of multiple GnRH antagonists such as Myfembree for the treatment of heavy bleeding associated with fibroids will also drive the market growth.

Uterine Fibroids Treatment Market Report Highlights

GnRH antagonists’ segment is anticipated to witness faster growth owing to its high efficacy and effective treatment option.

Sub-mucosal fibroids segment accounted for the larger market share. This is primarily due its high prevalence rate and severity. It is most common among Asian women

Retail pharmacies segment expected to garner substantial share, owing to easy availability of drugs and other combination therapies

North America is expected to grow larger revenue, owing to high prevalence rate in the US. presence of better medical facilities, and awareness among individuals about ill effects.

The global players include Myovant Sciences, Pfizer, Abbvie, Ferring, AstraZeneca, Bayer, Amring Pharmaceuticals, and Watson Pharma.

Polaris Market Research has segmented the uterine fibroids treatment market report based on drug type, drug class, end use, and region:

Uterine Fibroids Treatment, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

Subserosal Fibroids

Intramural Fibroids

Submucosal Fibroids

Pedunculated Fibroids

Uterine Fibroids Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Gonadotropin-releasing Hormone (GnRH) Agonists

Gonadotropin-releasing Hormone (GnRH) Antagonists

Progestin-releasing Intrauterine Device (IUD) & Contraceptives

Non-hormonal Medications

Others

Uterine Fibroids Treatment, End Use Outlook (Revenue - USD Billion, 2019 - 2032)

Hospital Pharmacies

Retail Pharmacies

Others

Uterine Fibroids Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa


1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data End Uses
3.2.1. Primary End Uses
3.2.2. Secondary End Uses
4. Global Uterine Fibroid Treatment Market Insights
4.1. Uterine Fibroid Treatment Market – End Use Snapshot
4.2. Uterine Fibroid Treatment Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Increasing Population Base For Uterine Fibroids Patients
4.2.1.2. Growing Awareness Initiatives Related To Uterine Fibroids Diagnosis And Treatment
4.2.2. Restraints and Challenges
4.2.2.1. Stringent Regulatory Framework
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Uterine Fibroid Treatment Market End Use Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Uterine Fibroid Treatment Market, by Drug Class
5.1. Key Findings
5.2. Introduction
5.2.1. Global Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
5.3. Gonadotropin-releasing Hormone (GnRH) Agonists
5.3.1. Global Uterine Fibroid Treatment Market, by Gonadotropin-releasing Hormone (GnRH) Agonists, by Region, 2019-2032 (USD Billion)
5.4. Gonadotropin-releasing Hormone (GnRH) Antagonists
5.4.1. Global Uterine Fibroid Treatment Market, by Gonadotropin-releasing Hormone (GnRH) Antagonists, by Region, 2019-2032 (USD Billion)
5.5. Progestin-releasing Intrauterine Device (IUD) & Contraceptives
5.5.1. Global Uterine Fibroid Treatment Market, by Progestin-releasing Intrauterine Device (IUD) & Contraceptives, by Region, 2019-2032 (USD Billion)
5.6. Non-hormonal Medications
5.6.1. Global Uterine Fibroid Treatment Market, by Non-hormonal Medications, by Region, 2019-2032 (USD Billion)
5.7. Others
5.7.1. Global Uterine Fibroid Treatment Market, by Others, by Region, 2019-2032 (USD Billion)
6. Global Uterine Fibroid Treatment Market, by Drug Type
6.1. Key Findings
6.2. Introduction
6.2.1. Global Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
6.3. Subserosal Fibroids
6.3.1. Global Uterine Fibroid Treatment Market, by Subserosal Fibroids, by Region, 2019-2032 (USD Billion)
6.4. Intramural Fibroids
6.4.1. Global Uterine Fibroid Treatment Market, by Intramural Fibroids, by Region, 2019-2032 (USD Billion)
6.5. Submucosal Fibroids
6.5.1. Global Uterine Fibroid Treatment Market, by Submucosal Fibroids, by Region, 2019-2032 (USD Billion)
6.6. Pedunculated Fibroids
6.6.1. Global Uterine Fibroid Treatment Market, by Pedunculated Fibroids, by Region, 2019-2032 (USD Billion)
7. Global Uterine Fibroid Treatment Market, by End Use
7.1. Key Findings
7.2. Introduction
7.2.1. Global Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
7.3. Hospital Pharmacies
7.3.1. Global Uterine Fibroid Treatment Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Billion)
7.4. Retail Pharmacies
7.4.1. Global Uterine Fibroid Treatment Market, by Retail Pharmacies, By Region, 2019-2032 (USD Billion)
7.5. Others
7.5.1. Global Uterine Fibroid Treatment Market, by Others, By Region, 2019-2032 (USD Billion)
8. Global Uterine Fibroid Treatment Market, by Geography
8.1. Key findings
8.2. Introduction
8.2.1. Uterine Fibroid Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
8.3. Uterine Fibroid Treatment Market – North America
8.3.1. North America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.3.2. North America: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.3.3. North America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.3.4. Uterine Fibroid Treatment Market – U.S.
8.3.4.1. U.S.: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.3.4.2. U.S.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.3.4.3. U.S.: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.3.5. Uterine Fibroid Treatment Market – Canada
8.3.5.1. Canada: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.3.5.2. Canada.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.3.5.3. Canada: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.4. Uterine Fibroid Treatment Market – Europe
8.4.1. Europe: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.4.2. Europe.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.4.3. Europe: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.4.4. Uterine Fibroid Treatment Market – UK
8.4.4.1. UK: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.4.4.2. UK.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.4.4.3. UK: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.4.5. Uterine Fibroid Treatment Market – France
8.4.5.1. France: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.4.5.2. France.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.4.5.3. France: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.4.6. Uterine Fibroid Treatment Market – Germany
8.4.6.1. Germany: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.4.6.2. Germany.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.4.6.3. Germany: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.4.7. Uterine Fibroid Treatment Market – Italy
8.4.7.1. Italy: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.4.7.2. Italy.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.4.7.3. Italy: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.4.8. Uterine Fibroid Treatment Market – Spain
8.4.8.1. Spain: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.4.8.2. Spain.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.4.8.3. Spain: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.4.9. Uterine Fibroid Treatment Market – Netherlands
8.4.9.1. Netherlands: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.4.9.2. Netherlands.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.4.9.3. Netherlands: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.4.10. Uterine Fibroid Treatment Market – Russia
8.4.10.1. Russia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.4.10.2. Russia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.4.10.3. Russia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.5. Uterine Fibroid Treatment Market – Asia Pacific
8.5.1. Asia Pacific: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.5.2. Asia Pacific.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.5.3. Asia Pacific: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.5.4. Uterine Fibroid Treatment Market – China
8.5.4.1. China: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.5.4.2. China.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.5.4.3. China: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.5.5. Uterine Fibroid Treatment Market – India
8.5.5.1. India: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.5.5.2. India.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.5.5.3. India: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.5.6. Uterine Fibroid Treatment Market – Malaysia
8.5.6.1. Malaysia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.5.6.2. Malaysia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.5.6.3. Malaysia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.5.7. Uterine Fibroid Treatment Market – Japan
8.5.7.1. Japan: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.5.7.2. Japan.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.5.7.3. Japan: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.5.8. Uterine Fibroid Treatment Market – Indonesia
8.5.8.1. Indonesia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.5.8.2. Indonesia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.5.8.3. Indonesia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.5.9. Uterine Fibroid Treatment Market – South Korea
8.5.9.1. South Korea: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.5.9.2. South Korea.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.5.9.3. South Korea: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.6. Uterine Fibroid Treatment Market – Middle East & Africa
8.6.1. Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.6.2. Middle East & Africa.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.6.3. Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.6.4. Uterine Fibroid Treatment Market – Saudi Arabia
8.6.4.1. Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.6.4.2. Saudi Arabia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.6.4.3. Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.6.5. Uterine Fibroid Treatment Market – UAE
8.6.5.1. UAE: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.6.5.2. UAE.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.6.5.3. UAE: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.6.6. Uterine Fibroid Treatment Market – Israel
8.6.6.1. Israel: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.6.6.2. Israel.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.6.6.3. Israel: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.6.7. Uterine Fibroid Treatment Market – South Africa
8.6.7.1. South Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.6.7.2. South Africa.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.6.7.3. South Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.7. Uterine Fibroid Treatment Market – Latin America
8.7.1. Latin America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.7.2. Latin America.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.7.3. Latin America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.7.4. Uterine Fibroid Treatment Market – Mexico
8.7.4.1. Mexico: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.7.4.2. Mexico.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.7.4.3. Mexico: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.7.5. Uterine Fibroid Treatment Market – Brazil
8.7.5.1. Brazil: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.7.5.2. Brazil.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.7.5.3. Brazil: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.7.6. Uterine Fibroid Treatment Market – Argentina
8.7.6.1. Argentina: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
8.7.6.2. Argentina.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
8.7.6.3. Argentina: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Myovant Sciences
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Drug Class Benchmarking
10.1.4. Recent Development
10.2. Pfizer
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Drug Class Benchmarking
10.2.4. Recent Development
10.3. Abbvie
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Drug Class Benchmarking
10.3.4. Recent Development
10.4. Ferring
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Drug Class Benchmarking
10.4.4. Recent Development
10.5. AstraZeneca
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Drug Class Benchmarking
10.5.4. Recent Development
10.6. Bayer
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Drug Class Benchmarking
10.6.4. Recent Development
10.7. Amring Pharmaceuticals
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Drug Class Benchmarking
10.7.4. Recent Development
10.8. Watson Pharma
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Drug Class Benchmarking
10.8.4. Recent Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings